Healthcare
Live Price
Offline$13.49
+0.00% today
1Y Change
-27.38%
Window
Jun 30, 2025 โ Jun 23, 2026
Coverage: 252 bars ยท Jun 30, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CellaVision AB (publ) (CLVSF) is a Healthcare stock with a market cap of $2.88B. The stock last traded around $13.49 and down 27.4% across the available one-year price window (Jun 30, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +4.9%, EPS growth of +8.8%, a dividend yield of 2.3%. What stands out right now is revenue +4.9%, EPS +8.8%, free cash flow -5.3% with operating margin 23.7% and ROIC 13.4%. The dividend is present but secondary, with a yield around 2.3%. Valuation is more restrained than many high-expectation growth names at P/E 21.5 and price/sales 3.9. Stock Foundry combines CLVSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.9% vs +7.6% peer median
Operating Margin
Above sector median
+23.7% vs +19.4% peer median
P/E
Below sector median
21.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.9% and EPS at +8.8%, with operating margin around 23.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.3%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.7% over the next 5 trading days and finished higher after 0 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | -16.4% | -16.4% | -16.4% |
2026 Feb 5, 2026 | +37.3% | +0.0% | +0.0% | +0.0% |
2025 Nov 5, 2025 | +24.4% | +0.0% | -12.7% | -12.7% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
CLVSF is 46.12 pts behind over the shared 1Y window.
CLVSF had 20.90 pts deeper max drawdown than SPY.
CLVSF beat SPY in 0 of 2 calendar years shown and trailed in 2.
CLVSF
-27.38%
Normalized return
SPY
+18.73%
S&P 500
Excess Return
-46.12 pts
Relative to SPY
CLVSF Max Drawdown
-30.03%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for CLVSF and SPY.
| Year | CLVSF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -16.80% | +6.71% | -23.50 pts | SPY |
| 2025 | -12.73% | +11.19% | -23.92 pts | SPY |
Company Overview
CellaVision AB (publ)
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.